Veterinary Medicines

BELACOL 12 %, 120 mg/g geriamieji milteliai galvijams, kiaulėms ir vištoms

Authorised
  • COLISTIN SULFATE
Download as PDF

Product identification

Medicine name:
BELACOL 12 %, 120 mg/g geriamieji milteliai galvijams, kiaulėms ir vištoms
Active substance:
  • COLISTIN SULFATE
Target species:
  • Cattle
  • Pig
  • Cattle (calf)
  • Chicken
Route of administration:
  • In-feed use
  • In drinking water/milk use
  • In drinking water use

Product details

Active substance and strength:
  • COLISTIN SULFATE
    120.00
    milligram(s)
    /
    1.00
    gram(s)
Pharmaceutical form:
  • Oral powder
Withdrawal period by route of administration:
  • In-feed use
    • Cattle
      • Meat
        2
        day
      • Milk
        0
        day
    • Pig
      • Meat
        2
        day
  • In drinking water/milk use
    • Cattle (calf)
      • Meat
        2
        day
  • In drinking water use
    • Chicken
      • Meat
        2
        day
      • Egg
        0
        day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QA07AA10
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Lithuania
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Legal basis reviewed according to Acquis communautaire
Marketing authorisation holder:
  • Bela-Pharm GmbH & Co. KG
Marketing authorisation date:
Manufacturing sites for batch release:
  • Bela-Pharm GmbH & Co. KG
Responsible authority:
  • State Food And Veterinary Service
Authorisation number:
  • LT/2/98/0742/002-006
Date of authorisation status change:

Documents

RV0742.pdf

Lithuanian (PDF)
Published on: 3/08/2022
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."